Jubilant Life Sciences

Jubilant Life Sciences arm gets US FDA nod for coronary drug

Jubilant Life Sciences today said its wholly-owned subsidiary has received approval from the US health regulator for RUBY-FILL -- Rubidium 82 generator and elution system -- used in diagnosis of coronary artery disease in the US market.

Jubilant Life receives USFDA nod for hypertension tablets

As on 30 June, 2016, Jubilant Life Sciences had a total of 770 filings for Oral Solids of which 578 have been approved in various regions globally

Jubilant to market Technegas in US, signs pact with Cyclopharm

The company said DraxImage will provide at risk up to $4.5 million to fund the USFDA clinical trial currently under development with any additional costs to be funded by both parties equally.

Jubilant Life Sciences gets $70 mn manufacturing contract

Jubilant Life Sciences said on Wednesday its unit has signed a $70-million contract to manufacture an over-the-counter women's healthcare product for a US-based company.<br /><br /> <br /><br /> The product will be manufactured at its facility in Canada for a period of four years, it said in a statement.<br /><br /> <br /><br /> The contract can be extended for another two years for a higher quantity, it said.<br /><br /> <br /><br /> It did not name the US firm or give details of the product.<br /><br /> <br /><br /> "This contract is an outcome of our strategy to expand offerings across products and geographies. We are happy to extend services for an over-the-counter product with a leading customer in North America," Shyam Bhartia, chairman and managing director, Jubilant Life Sciences, said.<br /><br /> <br /><br /> This is the second large deal for Jubilant in the last one month after it signed a $33 million manufacturing contract with a US firm.<br /><br /> <br /><br />